Argenx (ARGX)
(Delayed Data from NSDQ)
$536.70 USD
+9.45 (1.79%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $536.78 +0.08 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$536.70 USD
+9.45 (1.79%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $536.78 +0.08 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth D Momentum F VGM
Zacks News
Zacks.com featured highlights include Argenx SE Alphatec and Olin
by Zacks Equity Research
Argenx SE Alphatec and Olin have been highlighted in this Screen of The Week article.
3 Best Earnings Acceleration Stocks to Buy in a Strong Q4
by Tirthankar Chakraborty
With the advent of a strong fourth quarter, it's prudent to invest in stocks exhibiting solid earnings acceleration such as Argenx, Alphatec Holdings and Olin Corporation.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
by Zacks Equity Research
Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year.
Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?
by Zacks Equity Research
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for July 31st
by Zacks Equity Research
ARGX, VZLA, and SBFG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2024.
New Strong Buy Stocks for July 31st
by Zacks Equity Research
SBFG, APOG, ARGX, VZLA and SVM have been added to the Zacks Rank #1 (Strong Buy) List on July 31, 2024.
Argenx (ARGX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Argenx (ARGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
by Zacks Equity Research
Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
by Zacks Equity Research
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
by Zacks Equity Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.